Brokerages Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $36.46

Janux Therapeutics, Inc. (NASDAQ:JANX) has earned a consensus recommendation of “Moderate Buy” from the fifteen research firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $36.4615.

JANX has been the subject of several recent analyst reports. Wolfe Research raised shares of Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 target price for the company in a report on Monday, August 24th. TD Cowen upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Stifel Nicolaus set a $35.00 price target on shares of Janux Therapeutics in a research note on Friday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Janux Therapeutics in a report on Monday, July 20th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $26.00 target price (down from $80.00) on shares of Janux Therapeutics in a research report on Thursday, June 25th.

Janux Therapeutics Stock Down 1.6%

Shares of JANX opened at $16.59 on Monday. The business’s fifty day moving average is $16.99 and its 200 day moving average is $15.34. The stock has a market cap of $1.01 billion, a P/E ratio of -10.12 and a beta of 2.53. Janux Therapeutics has a 12-month low of $12.12 and a 12-month high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10). The company had revenue of $10.27 million for the quarter, compared to the consensus estimate of $19.07 million. On average, analysts expect that Janux Therapeutics will post -1.7 EPS for the current year.

Institutional Trading of Janux Therapeutics

Hedge funds have recently bought and sold shares of the company. Versant Capital Management Inc lifted its position in Janux Therapeutics by 42.8% during the second quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock valued at $40,000 after purchasing an additional 784 shares in the last quarter. ProShare Advisors LLC grew its stake in shares of Janux Therapeutics by 18.3% during the 4th quarter. ProShare Advisors LLC now owns 10,495 shares of the company’s stock valued at $145,000 after acquiring an additional 1,621 shares during the period. Quantinno Capital Management LP grew its stake in shares of Janux Therapeutics by 7.6% during the 1st quarter. Quantinno Capital Management LP now owns 26,064 shares of the company’s stock valued at $362,000 after acquiring an additional 1,846 shares during the period. Nano Cap New Millennium Growth Fund L P purchased a new stake in Janux Therapeutics in the 4th quarter worth approximately $34,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in Janux Therapeutics in the 4th quarter worth approximately $51,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc (NASDAQ: JANX) is a clinical-stage biotechnology company developing immunotherapies designed to activate the body’s T cells against cancer while limiting activity in healthy tissues. The company’s approach is intended to address challenges associated with conventional T-cell engagers, including systemic toxicity and limited tolerability.

Janux’s programs are based on its Tumor Activated T Cell Engager (TRACTr) platform. These therapeutic molecules are designed to remain inactive in circulation and become activated within the tumor microenvironment, where they can direct T cells to recognize and attack cancer cells.